沙美特罗联合噻托溴铵对慢性阻塞性肺疾病患者血清MMP-2,MMP-9及IL-8水平的影响  

Effects of Salmeterol and Tiotropium Bromide on Serum Levels of MMP-2,MMP-9 and IL-8 in Patients with COPD

作　　者：王艳[1] 史玉红[1] 李圣[2] 徐靖华[2] 李建林[3] 

机构地区：[1]辽宁中医药大学附属第四医院药剂科,辽宁沈阳110101 [2]辽宁中医药大学附属第四医院心血管内科,辽宁沈阳110101 [3]辽宁中医药大学附属第四医院呼吸内科,辽宁沈阳110101

出　　处：《现代生物医学进展》2017年第1期145-147,165,共4页Progress in Modern Biomedicine

基　　金：辽宁省科技厅计划项目(2013226012)

摘　　要：目的:探讨沙美特罗联合噻托溴铵对慢性阻塞性肺疾病患者血清炎症因子水平及肺功能的影响。方法:选择2014年5月-2016年5月我院收治的慢性阻塞性肺病患者83例作为研究对象,根据治疗方法不同,将所选患者分为研究组(45例)和对照组(38例)。研究组患者采用沙美特罗联合噻托溴铵吸入治疗,对照组患者采用沙美特罗治疗。观察并比较两组患者治疗前后血清MMP-2,MMP-9及IL-8水平及肺功能指标的变化情况。结果:治疗前两组患者血清MMP-2,MMP-9及IL-8水平比较,差异无统计学意义(P>0.05);治疗后两组患者血清MMP-2,MMP-9及IL-8水平均低于治疗前,且研究组低于对照组,差异均具有统计学意义(P<0.05)。与治疗前比较,两组患者治疗后FEV1/FVC,FEV1及MVV均升高,差异具有统计学意义(P<0.05);与对照组比较,研究组患者治疗后FEV1/FVC,FEV1及MVV较高,差异具有统计学意义(P<0.05)。结论:沙美特罗联合噻托溴铵治疗慢性阻塞性肺疾病的临床效果显著,不仅能够降低患者血清炎症因子水平,还可改善患者肺功能,值得临床推广应用。Objective： To investigate the effect of salmeterol combined with tiotropium bromide on serum levels of inflammatory factors and pulmonary function in patients with chronic obstructive pulmonary disease. Methods： 83 cases with chronic obstructive pulmonary disease who were treated in our hospital from May 2014 to May 2016 were selected, and according to the different treatment methods, the selected patients were divided into the study group（45 cases） and the control group（38 cases）. The patients in the study group were treated with salmeterol combined with the tiotropium bromide, and the control group were treated with salmeterol. Then the serum levels of MMP-2, MMP-9 and IL-8 and the pulmonary function indexes of patients in the two groups were observed and compared before and after the treatment. Results： There was no statistically significant difference about the serum levels of MMP-2, MMP-9and IL-8 in the two groups before the treatment（P〈0.05）; After treatment, the serum levels of MMP-2, MMP-9 and IL-8 in the two groups decreased, and the study group was lower than that of the control group, and the differences were statistically significant（P〈0.05）.Compared with before treatment, the FEV1 / FVC, FEV1 and MVV in the two groups increased after the treatment, and the differences were statistically significant（P〈0.05）; Compared with the control group, the FEV1 / FVC, FEV1 and MVV in the study groups after treatment were higher, and the differences were statistically significant（P〈0.05）. Conclusion： Salmeterol combined with tiotropium bromide have significant clinical effect on the treatment of chronic obstructive pulmonary disease, which can reduce the level of serum inflammatory factors and improve the pulmonary function of patients with COPD, and it is worthy of clinical application.

关 键 词：慢性阻塞性肺疾病 炎症因子 肺功能 沙美特罗 噻托溴铵 

分 类 号：R563[医药卫生—呼吸系统]